FDA supplemental appropriation for FY 1985
Executive SummaryAdditional $3.54 mil. for agency salaries in fiscal year 1985, which ends Sept. 30, is provided by a supplemental appropriations bill reported out of the House Appropriations Cmte. on May 21.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.